LQDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Liquidia Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$34.13−0.22 (-0.64%)
Close on Oct 19, 2026
- Market cap
- $3.46B
- P/E (TTM)
- 24.6
- Dividend yield
- –
Liquidia Corp revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $170.38M | $129.88M | $90.10M | $51.67M | $6.52M | – | – | – | – | – | 99.2% | +2514.4% |
| Service revenue, net | $1.30M | $2.98M | $1.92M | $2.67M | $2.32M | $3.12M | $2.92M | $4.45M | $3.66M | – | 0.8% | -44.1% |
By region
From the segment and revenue-disaggregation notes of Liquidia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.